Numaferm has developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs. (Evonik)
Financing Start Up

Evonik Invests in Numaferm

The newly incorporated company ‘Numaferm’ enables plannable biotechnological production of peptides at higher yields and at lower costs. Evonik invests in this biotechnology company as it identifies it as a growth opportunity for its health care and specialty additives segment.

Read on